PubRank

Robert J Manning

Author PubWeight™ 23.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012 4.26
2 MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013 1.79
3 A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 2013 1.44
4 The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2013 1.38
5 Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007 1.29
6 Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007 1.26
7 IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica 2009 0.94
8 Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol 2011 0.92
9 Fabrication of biomolecular nanostructures by scanning near-field photolithography of oligo(ethylene glycol)-terminated self-assembled monolayers. Langmuir 2007 0.91
10 CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 2008 0.89
11 CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006 0.89
12 Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011 0.88
13 Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 2011 0.87
14 Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 2012 0.87
15 Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009 0.87
16 Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood 2008 0.85
17 Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2007 0.83
18 Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol 2009 0.81
19 Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009 0.81
20 Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. Cancer Epidemiol 2011 0.79
21 Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. Clin Lymphoma Myeloma Leuk 2013 0.77
22 Analysis of the dimensional dependence of semiconductor optical amplifier recovery speeds. Opt Express 2007 0.75
23 High-bandwidth generation of duobinary and alternate-mark-inversion modulation formats using SOA-based signal processing. Opt Express 2011 0.75
24 Four-wave mixing for clock recovery of phase modulated optical OFDM superchannel. Opt Express 2014 0.75
25 Self-starting optical-electrical-optical homodyne clock recovery for phase-modulated signals. Opt Lett 2017 0.75
26 All-optical phase discrimination using SOA. Opt Express 2013 0.75
27 Fast gain recovery rates with strong wavelength dependence in a non-linear SOA. Opt Express 2010 0.75
28 Practical and cost-effective high-fidelity optical carrier dissemination using coherent communication techniques. Opt Express 2015 0.75
29 High speed cross-amplitude modulation in concatenated SOA-EAM-SOA. Opt Express 2012 0.75